Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 50M | 52M | 38M | 26M |
| Gross Profit | 27M | 31M | 19M | 12M |
| Operating Income | -31M | -29M | -15M | -20M |
| EBITDA | -20M | 893K | 821K | -18M |
| Net Income | -34M | -21M | -18M | -52M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Minerva Surgical, Inc. (UTRS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -3.5%, EPS growth of -58.1%, a dividend yield of 0.0%. What stands out right now is revenue -3.5%, EPS -58.1%, free cash flow -55.2% with operating margin -61.4% and ROIC -54.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UTRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UTRS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UTRS Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UTRS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.0M
-31.1% YoY
FY Net Income
-$52.0M
-185.0% YoY
Free Cash Flow
-$20.0M
-57.7% YoY
Revenue Growth
-3.5%
EPS Growth
-58.1%
Gross Margin
54.2%
Net Margin
-67.8%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 50M | 52M | 38M | 26M |
| Gross Profit | 27M | 31M | 19M | 12M |
| Operating Income | -31M | -29M | -15M | -20M |
| EBITDA | -20M | 893K | 821K | -18M |
| Net Income | -34M | -21M | -18M | -52M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Cash & Equivalents | 7M | 41M | 17M | 27M |
| Total Assets | 69M | 115M | 92M | 47M |
| Total Liabilities | 52M | 71M | 314M | 251M |
| Shareholder Equity | 17M | 44M | -222M | -205M |
| Total Debt | 40M | 39M | 97M | 76M |
| Net Debt | 33M | -1M | 80M | 49M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20M
-61.7% YoY
Capital Expenditures
223K
+50.8% YoY
Free Cash Flow
20M
-57.7% YoY
Key ratios
Gross Margin
54.2%
Operating Margin
-61.4%
Net Margin
-67.8%
ROE
-111.3%
Debt / Equity
2.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.